We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Balversa

News List

FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer drugs
April 17, 2019
FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer.
Balversa receives U.S. FDA approval for the treatment of patients with Urothelial Carcinoma biospectrumasia
April 16, 2019
The approval follows FDA Breakthrough Therapy Designation in March 2018 and Priority Review Designation of the New Drug Application submitted in September 2018.
Johnson & Johnson's Balversa becomes first targeted therapy for metastatic bladder cancer in US firstwordpharma
April 14, 2019
Johnson & Johnson said Friday that it received accelerated approval by the FDA regarding its marketing application for ……